Logo

GNTA

Genenta Science S.p.A.

GNTA

Genenta Science S.p.A. • NASDAQ
$2.01 ▲ 3.61% (+0.07)
Market Cap $38.48 M
52w High $10.00
52w Low $1.35
Dividend Yield 0%
P/E -3.65
Volume 72.38K
Outstanding Shares 19.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $0 $5.246M ▲ $-4.874M ▼ 0% $-0.27 ▼ $-5.224M ▼
Q2-2024 $0 $4.518M ▼ $-4.039M ▲ 0% $-0.22 ▲ $-4.496M ▲
Q4-2023 $0 $4.933M ▼ $-4.886M ▲ 0% $-0.27 ▲ $-4.911M ▼
Q2-2023 $0 $6.716M ▲ $-6.696M ▼ 0% $-0.37 ▼ $-3.39M ▲
Q4-2022 $0 $6.387M $-6.365M 0% $-0.34 $-6.887M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $12.66M ▼ $14.824M ▼ $2.328M ▲ $12.496M ▼
Q2-2024 $16.906M ▼ $19.017M ▼ $2.2M ▲ $16.817M ▼
Q4-2023 $18.776M ▼ $22.347M ▼ $1.915M ▼ $20.432M ▼
Q2-2023 $22.212M ▼ $26.726M ▼ $1.922M ▼ $24.804M ▼
Q4-2022 $29.795M $33.438M $2.3M $31.138M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-8.908M ▼ $-4.182K ▼ $2.583K ▼ $270.614K ▲ $4.576M ▲ $-6.243M ▼
Q2-2024 $-4.038K ▲ $-2.058K ▲ $4.299K ▲ $270.885 ▲ $6.187K ▲ $-2.06K ▲
Q4-2023 $-4.886K ▲ $-3.624K ▲ $-4.891K ▲ $0 $-12.213K ▲ $-3.626K ▲
Q2-2023 $-6.696M ▼ $-7.51M ▼ $-9.908M ▼ $0 $-17.418M ▼ $-7.522M ▼
Q4-2022 $-6.365K $-4.852K $-24.256 $0 $-2.438K $-4.876K

Five-Year Company Overview

Income Statement

Income Statement Genenta is still a pure research-stage biotech: it has not generated product revenue over the past several years and runs a recurring operating loss each year. Expenses appear relatively steady and are driven mainly by R&D and general running costs, which is typical for a small clinical‑stage company. Losses per share have moved around but remain clearly negative, reflecting ongoing spending without any commercial income yet.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base and a history of holding most resources in cash. There is no financial debt, so the company is not burdened by interest payments or leverage risk. However, total assets and equity have been drifting down, which signals that the capital raised in the past is being drawn down to fund operations and will eventually need to be replenished if development continues at the same pace.

Cash Flow

Cash Flow Cash flows show a consistent pattern of money going out to pay for operations and development, with no offsetting inflows from a commercial business. Free cash flow is negative and broadly in line with the operating loss, and the company does not appear to invest heavily in physical assets. This is a classic cash‑burn profile: continuation of current activities depends on raising new capital or obtaining non-dilutive funding over time.

Competitive Edge

Competitive Edge Competitively, Genenta aims to stand out with a first‑in‑class cell therapy that targets the tumor microenvironment rather than just the cancer cells themselves. Its position is strengthened by a focused intellectual property portfolio, orphan drug designations, and exclusive licenses that can provide regulatory and commercial advantages if the therapy succeeds. At the same time, the company operates in one of the most crowded and well‑funded areas of biotech—cancer immunotherapy—where it faces large, established rivals and the usual high clinical and regulatory risks. Overall, it has a differentiated scientific angle but must still prove it can translate this into clear, repeatable clinical benefits.

Innovation and R&D

Innovation and R&D Innovation is the core of the Genenta story. The company is engineering patients’ blood stem cells so that a specific immune cell type can carry an anti‑cancer signal directly into tumors, with Temferon as the lead program. Early clinical data in difficult cancers like glioblastoma are encouraging but still early‑stage and limited in scale, so they should be viewed as promising but not definitive. The platform is flexible in principle, with potential for use in other tumors and in combination with other drugs, and the work on more scalable manufacturing points to a longer‑term vision beyond a single product. As with most cutting‑edge biotech, the scientific upside is significant but paired with high uncertainty about timing, cost, and ultimate success.

Summary

Genenta is a small, clinical‑stage biotech whose financial profile is shaped almost entirely by R&D: no revenue yet, steady losses, negative cash flow, and a shrinking but debt‑free balance sheet. Its value proposition rests on a distinctive cell‑therapy platform targeting the tumor microenvironment, backed by academic expertise, patents, orphan designations, and manufacturing collaborations. The company’s prospects hinge on future clinical readouts, regulatory progress, and its ability to secure ongoing funding or partnerships to sustain development. Overall, the story is high‑risk and high‑uncertainty, with current financials reflecting an early‑stage research enterprise rather than a commercial operation.

NEWS

November 24, 2025 · 4:00 AM UTC

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Read more

October 26, 2025 · 8:30 PM UTC

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Read more

October 24, 2025 · 4:00 AM UTC

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Read more